




Nicole Robertson<sup>1,2,3</sup>, J. Zachary Porterfield<sup>1</sup>, Alex Kayongo<sup>3,4</sup>, Bruce Kirenga<sup>4,5</sup>, Robert Kalyesubula<sup>4</sup>, William Checkley<sup>2,3</sup>, Alice Thornton<sup>1</sup>, Trishul Siddharthan<sup>2,3</sup>

1. University of Kentucky College of Medicine 2. Johns Hopkins School of Medicine 3. Center for Global Non-Communicable Disease Research and Training, Johns Hopkins University 4. Makerere University Lung Institute 5. Department of Physiology, College of Health Sciences, Makerere University

## BACKGROUND


- Pulmonary tuberculosis (TB) is the leading infectious cause of death globally with an estimated 1.7 billion people currently infected with Mycobacterium tuberculosis and at risk of developing TB<sup>1,2</sup>
- While the treatment of drug-susceptible pulmonary TB is highly effective, up to 50% of TB survivors have varying degrees of residual pathological and functional conditions potentially leading to chronic sequelae<sup>3</sup>
- Post-TB patients have reported respiratory symptoms, reduced quality of life, and increased risk of mortality<sup>4</sup>

**Objective:** To describe the prevalence of post-TB exposure and lung function in individuals with post-TB exposure status in Uganda



## METHODS

- Secondary data analysis of the Lung Function in Nakaseke and Kampala (LiNK) study, which is a population-based cohort in urban and rural settings in Uganda.
- Trained research assistants randomly selected homes and administered standard questionnaires to adults 35 years or older that were full-time residents of each setting
- Prior TB diagnosis and treatment was self-reported by participants.
- The research team collected pre-bronchodilator forced vital capacity (FVC), forced expiratory volume in 1 second (FEV<sub>1</sub>), and the percentage of FVC exhaled in the first second (FEV<sub>1</sub>/FVC) according to American Thoracic Society guidelines



## RESULTS

### Demographic Characteristics of Participants



- In the LiNK study, 11.6% (177/1526) participants were excluded due to lack of acceptable and reproducible spirometry data and/or missing prior history of TB status. 1349 participants were ultimately included in our analysis.
- 42 participants (3.1%) self-reported successfully treated TB. The mean (± SD) number of years since TB diagnosis was 9.2 ± 8.1 years.
- Participants with no TB history had 2.7 kg/m<sup>2</sup> higher BMI, on average, relative to post-TB participants (p=0.001). Among the remaining demographic characteristics, there were no statistically significant differences between participants with and without prior TB history.

### Descriptive Characteristics of Participants

Demographic Characteristics	LiNK Cohort (N=1349)	Participants with Post-TB exposure status (n=42)
Age, years (mean [SD])	47.0 (10.4)	49.0 (17.9)
BMI, kg/cm <sup>2</sup> (mean [SD])	23.4 (5.6)	19.0 (1.1)
Standing height, cm (mean [SD])	161.9 (8.7)	169.5 (14.8)
Setting % (n)		
Urban	48.6 (656)	54.8 (23)
Rural	51.4 (693)	45.2 (19)
HIV status % (n)		
Positive	8.9 (120)	45.2 (19)
Negative	75.6 (1020)	54.8 (23)
Unknown	15.5 (209)	0 (0)
Prior COPD diagnosis % (n)	0.1 (1)	0 (0)
Currently Employed % (n)	87.4 (1179)	81.0 (34)
<b>Tobacco Use</b>		
Ever Smoker % (n)	8.1 (109)	19.0 (8)
Ever Daily Smoker % (n)	7.6 (103)	14.3 (6)
Current Smoker % (n)	7.9 (106)	4.8 (2)
Current Daily Smoker % (n)	5.0 (67)	4.8 (2)
Cigarettes smoked daily (mean [SD])	1.7 (2.1)	0 (0)
<b>Biomass Exposure</b>		
Any Biomass Use (wood, charcoal, dung) % (n)	51.0 (688)	59.5 (25)
Cooking Location % (n)		
Inside house	53.2 (718)	52.4 (22)
Outside house	9.9 (133)	14.3 (6)
Both inside and outside house	36.2 (488)	33.3 (6)
Unknown	0.7 (10)	0 (0)

### Decline in FEV<sub>1</sub>/FVC and Diagnosis of COPD by Spirometry

- Multivariate linear regression (FEV<sub>1</sub>/FVC) and multivariate logistic regression (COPD based on FEV<sub>1</sub>/FVC <0.7) identified age, BMI, HIV status, a rural home, having ever smoked, currently working and prior TB diagnosis as associated with obstructive lung pathology. (\* statistically significant change)




### Decline in FEV<sub>1</sub>/FVC and Diagnosis of COPD by Spirometry (Tabulated Data)

	Effect on FEV <sub>1</sub> /FVC			Effect on COPD Diagnosis (based on FEV <sub>1</sub> /FVC)		
	Beta Estimates	95% CI	Significant?	Odds Ratio	95% CI	Significant?
Age	-0.217	-0.254 -0.181	*	1.058	1.041 1.075	*
BMI	0.113	0.036 0.189	*	0.985	0.942 1.027	*
HIV	1.824	0.453 3.187	*	0.705	0.317 1.420	*
Urban/Rural	-2.268	-3.698 -0.893	*	3.411	1.577 7.419	*
Ever Smoker	-1.458	-2.498 -0.417	*	1.693	1.018 2.748	*
Working	-0.512	-1.690 0.652		1.896	1.044 3.340	*
Any Biomass Use	-0.012	-0.037 0.013		0.991	0.971 1.006	
Wood Fuel Use	-1.106	-2.401 0.187		1.964	1.015 3.640	
Coal Fuel Use	-0.255	-1.627 1.078		1.473	0.712 3.010	
Kerosene Fuel Use	1.133	-0.429 2.708		0.764	0.237 2.006	
Electricity Fuel Use	0.305	-2.235 2.890		1.486	0.229 5.474	
Prior TB	-8.176	-10.410 -5.932	*	7.885	3.550 17.392	*

### Effect of Prior TB on Spirometry and diagnosis of COPD

- A significant difference was noted in FEV<sub>1</sub>, FVC, and FEV<sub>1</sub>/FVC measurements based on prior TB status (left). Similarly, a diagnosis of COPD by spirometry (FEV<sub>1</sub>/FVC <0.7) was also different based on prior TB status (right, p<0.0001)



## DISCUSSION

- Several factors in our study were associated with changes in spirometry and development of COPD in a statistically significant way: Age, BMI, HIV, rural home, ever having smoked, currently working, and pulmonary TB
- Of these factors, a rural home, having ever smoked and pulmonary TB had the largest effect on the outcomes. TB had a particularly strong effect

## CONCLUSION

- Prior TB infection is significantly and strongly associated with development of COPD (OR 7.89, 95% CI 3.55 – 17.4)
- ~25% of the world's population has active TB infection
- Screening for chronic respiratory disease in patients identified with TB may be a crucial step in overall management of this patient population

## FUNDING

This research was supported by the New York Academy of Medicine David E. Rogers Fellowship, the Infectious Disease Society of America Foundation Grant for Emerging Researchers/Clinicians Mentorship (G.E.R.M.), the National Center for Advancing Translational Sciences (UL1TR001998), and the Dean of the College of Medicine at the University of Kentucky

## REFERENCES

- World Health Organization. Global Tuberculosis Report. Geneva: 2015. 2015. Accessed at: [http://www.who.int/tb/publications/global\\_report/en/](http://www.who.int/tb/publications/global_report/en/) [Accessed 26 July 2020].
- Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016;13(10):e1002152.
- Pasipanodya JG, McNabb SJ, Hilsenrath P, et al. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010;10:259.
- Singh SK, Naaraayan A, Acharya P, Menon B, Bansal V, Jesmajian S. Pulmonary Rehabilitation in Patients with Chronic Lung Impairment from Pulmonary Tuberculosis. Cureus. 2018;10(11):e3664.
- MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets — 2017. MMWR Morb Mortal Wkly Rep 2019;68:263–266.